Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.43 |
| ▸ | PTGDR | Q13258 | 3/20 | 0.43 |
| ▸ | DPP4 | P27487 | 2/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.41 |
| ▸ | MC4R | P32245 | 5/20 | 0.40 |
| ▸ | MC5R | P33032 | 2/20 | 0.40 |
| ▸ | MC3R | P41968 | 2/20 | 0.40 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.40 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.40 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CCR1 | P32246 | 3/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3118248 | 0.83 | STS (0.48) | TP53HTTMEN1KMT2A | |
| SCHEMBL6867393 | 0.83 | MC4R (0.48) | MC4RMC5RMC3R | |
| SCHEMBL1094791 | 0.75 | PTGDR2 (0.45) | PTGDR2PTGDRPTGER2GRM5LMNA | |
| SCHEMBL14540632 | 0.75 | HTR6 (0.46) | LMNATP53HTTKCNH2 | |
| SCHEMBL17398233 | 0.72 | POLB (0.44) | PTGDR2LMNATP53MEN1KMT2A | |
| SCHEMBL4680009 | 0.71 | MEN1 (0.46) | MEN1KMT2AKCNH2 | |
| SCHEMBL28432246 | 0.71 | RBP4 (0.54) | — | |
| SCHEMBL23212047 | 0.71 | RORC (0.50) | KMT2AKCNH2 | |
| SCHEMBL14540631 | 0.70 | MC4R (0.45) | MC4RMC5RMC3R | |
| SCHEMBL4072569 | 0.70 | OPRD1 (0.46) | DPP4DPP7MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6818658-B2 | TREATING OBESITY, DIABETES, SEXUAL DYSFUNCTION, INCLUDING ERECTILE DYSFUNCTION AND FEMALE SEXUAL DYSFUNCTION. | MERCK & CO., INC. | 2004-11-16 | — | — | US | disclosed |
| US-20030225060-A1 | Acylated piperidine derivatives as melanocortin-4 receptor agonists | MERCK SHARP & DOHME CORP. | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225060-A1 | Acylated piperidine derivatives as melanocortin-4 receptor agonists | MC4R, MC5R, MC3R | PTGDR2 791/4885PTGDR 375/4885DPP4 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.